[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100606800":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":24,"locations":29,"responsibleParty":46,"collaborators":10,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":10,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":10,"enrollmentInfo":58,"targetDuration":61,"studyType":62,"phases":10,"briefSummary":63,"conditions":64,"keywords":10,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"RenJi Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Trastuzumab deruxtecan",null,"Trastuzumab deruxtecan, recommended dose 5.4mg\u002Fkg, every 21 days",[13],"Drug: Trastuzumab deruxtecan",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":10},"DRUG","Trastuzumab deruxtecan is a combination of the targeted cancer drug trastuzumab (also known as Herceptin) and a chemotherapy drug called deruxtecan or DXd.",[9],[20],{"name":21,"affiliation":22,"role":23},"Wenjin Yin, M.D.","Renji Hospital,School of Medicine, Shanghai Jiaotong University","PRINCIPAL_INVESTIGATOR",[25],{"name":21,"role":26,"phone":27,"phoneExt":10,"email":28},"CONTACT","86(21)68385569","yinwenjin@renji.com",[30],{"facility":31,"status":32,"city":33,"state":10,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Renji Hospital, School of Medicine, Shanghai Jiaotong University","RECRUITING","Shanghai","200127","China","CN",{"type":38,"coordinates":39},"Point",[40,41],121.45806,31.22222,{"lat":41,"lon":40},[44],{"name":45,"role":26,"phone":27,"phoneExt":10,"email":28},"Wenjin Yin",{"type":47,"investigatorFullName":45,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Deputy Chief of Breast Surgery Department","100606800","trastuzumab-deruxtecan-in-advanced-breast-cancer-100606800",false,"NCT07180264","Trastuzumab Deruxtecan in Advanced Breast Cancer","Trastuzumab Deruxtecan in Patients With Advanced Breast Cancer: a Real-world Study","Inclusion Criteria:\n\n* Aged ≥18 and older\n* Breast cancer patients meeting current guideline recommendations and planning to receive trastuzumab deruxtecan\n* ECOG 0-1\n\nExclusion Criteria:\n\n* During pregnancy and lactation","ALL","18 Years",{"count":59,"type":60},118,"ESTIMATED","4 Years","OBSERVATIONAL","To evaluate the efficacy and safety of trastuzumab deruxtecan in advanced breast cancer patients.",[65],"Advanced Breast Cancer","2025-11-16",{"date":68,"type":69},"2025-11-18","ACTUAL",{"date":71,"type":69},"2025-08-28",{"date":73,"type":60},"2029-02",{"name":45,"class":6},1]